Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p55
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 55/66)
Character Range: 172839–177874

sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16075  P16075  CN16075  Rifampicin                   Meningococcal disease
                                                      The treatment must be for prophylaxis; AND
                                                      Patient must be a carrier of the disease; or
                                                      Patient must be in close contact with people who have the disease; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16078  P16078  CN16078  Penicillamine                The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16083  P16083  CN16083  Methadone                    Opioid dependence                                                                                                                                                                                                                                                                                                                                                                                                   Compliance with Authority Required procedures - Streamlined Authority Code 16083
                                                      The treatment must be within a framework of medical, social and psychological treatment.
                                                      The prescriber must request a quantity (in millilitres) sufficient for up to 28 days of supply per dispensing according to the patient's daily dose. Up to 5 repeats will be authorised. The maximum listed quantity or number of repeats must not be prescribed if lesser quantity or repeats are sufficient for the patient's needs.
C16085  P16085  CN16085  Avelumab                     Stage IV (metastatic) Merkel Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 16085
                                                      Continuing treatment
                                                      The treatment must be the sole PBS-subsidised therapy for this condition; AND
                                                      Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
                                                      Patient must not have developed disease progression while being treated with this drug for this condition; AND
                                                      The treatment must not exceed a maximum dose of 10 mg per kg every 2 weeks under this restriction. or
                                                      The treatment must not exceed a dose of 800 mg every 2 weeks under this restriction.
C16087  P16087  CN16087  Romosozumab                  Severe established osteoporosis                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures
                                                      Initial treatment - Second-line therapy
                                                      Patient must be at very high risk of fracture; AND
                                                      Patient must have a bone mineral density (BMD) T-score of -3.0 or less; AND
                                                      Patient must have had 2 or more fractures due to minimal trauma; AND
                                                      Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate